ORIC Pharmaceuticals, Inc.

113 articles about ORIC Pharmaceuticals, Inc.

• ORIC Pharmaceuticals Presents Preclinical Data Demonstrating ORIC-533 as a Potential Best-in-Class CD73 Inhibitor at the 64th American Society of Hematology (ASH) Annual Meeting

  12/13/2022

  ORIC Pharmaceuticals, Inc. presented preclinical ORIC-533 data demonstrating a potential best-in-class CD73 inhibitor profile for the treatment of multiple myeloma.

• ORIC Pharmaceuticals to Present at the 2022 Jefferies London Healthcare Conference

  11/8/2022

  ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 16, 2022, at 5:35 p.m. GMT.

• ORIC Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Update

  11/7/2022

  ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, reported financial results and operational updates for the quarter ended September 30, 2022.

• ORIC Pharmaceuticals to Present Preclinical Data on CD73 Inhibitor Program in Multiple Myeloma at the 64th American Society of Hematology (ASH) Annual Meeting

  11/3/2022

  ORIC Pharmaceuticals, Inc. announced a preclinical poster presentation on ORIC-533 at the 64th American Society of Hematology Annual Meeting to be held December 10-13, 2022, in New Orleans, LA.

• ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - October 07, 2022

  10/7/2022

  ORIC Pharmaceuticals, Inc. announced that on October 3, 2022, ORIC granted a total of 116,560 non-qualified stock options and 19,435 restricted stock units to five new non-executive employees who began their employment with ORIC in September 2022.

• ORIC Pharmaceuticals to Participate in Upcoming September 2022 Investor Conferences

  9/1/2022

  ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that management will participate in the following investor conferences in September.

• ORIC Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Update

  8/11/2022

  ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, reported financial results and operational updates for the quarter ended June 30, 2022.

• ORIC Pharmaceuticals to Present at the Jefferies Healthcare Conference

  6/2/2022

  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 9, 2022, at 8:00 a.m. ET.

• ORIC Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

  5/17/2022

  ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that Dominic Piscitelli, chief financial officer, will present a company overview at the H.C. Wainwright Global Investment Conference on Tuesday, May 24, 2022, at 7:00 a.m. ET.

• ORIC Pharmaceuticals Presents Promising Preclinical Data on Three Programs at the 2022 American Association for Cancer Research (AACR) Annual Meeting

  4/12/2022

  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, presented three preclinical poster presentations and one preclinical oral presentation at the 2022 American Cancer Research Association (AACR) Annual Meeting.

• 

  Neurana, Aurobindo and ORIC Face Tough Decisions, Layoffs

  3/23/2022

  Neurana Pharmaceuticals is facing dire financial straits following the failure of its Phase III treatment for muscle spasm relief associated with an acute, painful musculoskeletal condition.

• ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update

  3/21/2022

  ORIC Pharmaceuticals, Inc. today announced the discontinuation of ORIC-101 and also reported financial results and operational updates for the quarter and year ended December 31, 2021.

• ORIC Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Financial Results and Operational Update Conference Call

  3/17/2022

  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), today announced that management will host a conference call and webcast to discuss its fourth quarter and full year 2021 financial results and provide an operational update on Monday, March 21, 2022, at 5:00 p.m. ET.

• ORIC Pharmaceuticals Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting

  3/8/2022

  ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced three poster presentations and one oral presentation at the 2022 American Association for Cancer Research Annual Meeting taking place April 8-13, 2022, in New Orleans, LA.

• ORIC Pharmaceuticals to Participate in the Guggenheim 2022 Oncology Conference

  2/2/2022

  ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that management will participate in a virtual fireside chat at the Guggenheim 2022 Oncology Conference on Thursday, February 10, 2022, at 2:00 p.m. ET.

• ORIC Pharmaceuticals Announces Regulatory Clearance of Clinical Trial Application for ORIC-114 in Advanced Solid Tumors with EGFR or HER2 Exon 20 Alterations or HER2 Amplifications

  1/25/2022

  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), today announced clearance of its Clinical Trial Application (CTA) by the regulatory authorities of the Republic of Korea for ORIC-114, a brain penetrant, orally bioavailable, irreversible inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations.

• ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones

  1/10/2022

  ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, provided program updates and announced upcoming key milestones that are expected to substantially broaden and advance the company’s clinical pipeline.

• ORIC Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

  1/4/2022

  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob Chacko, M.D., chief executive officer, will present a company overview at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 3:00 p.m. ET.

• ORIC Pharmaceuticals Presents Data Supporting the Therapeutic Potential of ORIC-533 in Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting

  12/13/2021

  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance presented preclinical data with ORIC’s small molecule inhibitor of CD73 in multiple myeloma at the American Society of Hematology (ASH).

• ORIC Pharmaceuticals to Host ASH Conference Call with Key Opinion Leader to Discuss Potential of ORIC-533 in Multiple Myeloma

  12/9/2021

  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the company will host a conference call and webcast to discuss their CD73 inhibitor program in multiple myeloma.